Abstract

Malaria can cause life-threatening complications which are often associated with inflammatory reactions. More subtle, but also contributing to the burden of disease are chronic, often subclinical infections, which result in conditions like anemia and immunologic hyporesponsiveness. Although very frequent, such infections are difficult to study in endemic regions because of interaction with concurrent infections and immune responses. In particular, knowledge about mechanisms of malaria-induced immunosuppression is scarce. We measured circulating immune cells by cytometry in healthy, malaria-naïve, adult volunteers undergoing controlled human malaria infection (CHMI) with a focus on potentially immunosuppressive cells. Infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) were inoculated during two independent studies to assess malaria vaccine efficacy. Volunteers were followed daily until parasites were detected in the circulation by RT-qPCR. This allowed us to analyze immune responses during pre-patency and at very low parasite densities in malaria-naïve healthy adults. We observed a consistent increase in circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in volunteers who developed P. falciparum blood stage parasitemia. The increase was independent of preceding vaccination with a pre-erythrocytic malaria vaccine. PMN-MDSC were functional, they suppressed CD4+ and CD8+ T cell proliferation as shown by ex-vivo co-cultivation with stimulated T cells. PMN-MDSC reduced T cell proliferation upon stimulation by about 50%. Interestingly, high circulating PMN-MDSC numbers were associated with lymphocytopenia. The number of circulating regulatory T cells (Treg) and monocytic MDSC (M-MDSC) showed no significant parasitemia-dependent variation. These results highlight PMN-MDSC in the peripheral circulation as an early indicator of infection during malaria. They suppress CD4+ and CD8+ T cell proliferation in vitro. Their contribution to immunosuppression in vivo in subclinical and uncomplicated malaria will be the subject of further research. Pre-emptive antimalarial pre-treatment of vaccinees to reverse malaria-associated PMN-MDSC immunosuppression could improve vaccine response in exposed individuals.

Highlights

  • Malaria is responsible for ∼409,000 deaths, resulting from about 229 million new cases of malaria per year globally [1]

  • All samples were obtained from two independent clinical trials in which efficacy of Sanaria R Plasmodium falciparum Sporozoites (PfSPZ) Radiation attenuated PfSPZ (Vaccine) [radiation attenuated, aseptic, purified, cryopreserved P. falciparum (Pf) sporozoites (SPZ)] and PfSPZ-CVac were assessed by controlled human malaria infection (CHMI) (ClinicalTrials.gov identifiers NCT02858817 and NCT02704533)

  • Circulating Myeloid-derived suppressor cells (MDSC) kinetics were quantified during CHMI, done in a subset of participants of the two clinical malaria vaccine trials in healthy naïve volunteers that will be reported elsewhere [Mordmüller et al unpublished data and [53]]

Read more

Summary

Introduction

Malaria is responsible for ∼409,000 deaths, resulting from about 229 million new cases of malaria per year globally [1]. In malaria-endemic areas, a large fraction of infections in older children and adults is asymptomatic or remains unnoticed. Chronic low parasitemias with no or mild signs and symptoms can still have a strong impact, mostly through the development of anemia and suppression of immune responses against vaccines and other infectious diseases [13,14,15,16]. Both consequences of chronic plasmodial infections often remain unrecognized despite having an important long-lasting impact, in children [17,18,19]. Coinfections, high and variable malaria incidence, as well as other genetic and environmental factors, impede a systematic analysis, and large cohorts are required to circumvent these issues

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call